Thursday - April 30, 2026

Category Archives: Marketing & Sales

Lewy Body Dementia Pipeline 2026: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Jazz Pharma, Allergan, Noven Pharma, Takeda Pharma, Eli Lilly, Mallinckrodt Pharma

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Lewy Body Dementia pipeline constitutes key companies continuously working towards developing Lewy Body Dementia treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes … Continue reading →

Psoriasis Market: Investment-Ready Growth Trends to 2034 – DelveInsight | Sun Pharma, Bristol-Myers Squibb, UCB Biopharma, Affibody AB, Ventyx Biosciences, Aclaris Therapeutics, AbbVie, Novartis

The Key Psoriasis Companies in the market include – UCB Pharma, Novartis, Sun Pharmaceutical/ Almirall, Bausch Health, Boehringer Ingelheim, LEO Pharma, AnaptysBio, Nimbus Lakshmi/Takeda, MoonLake Immunotherapeutics, Can-Fite Biopharma, E-nitiate Biopharmaceuticals, SFA Therapeutics, Rubedo Life Sciences, Inc, and others.   DelveInsight’s … Continue reading →

Non-Alcoholic Steatohepatitis Pipeline Set for Transformational Expansion by 2026 with 75+ Therapies, Strong Clinical Momentum from Novo Nordisk, Viking Therapeutics, Inventiva Pharma | DelveInsight

Non-Alcoholic Steatohepatitis Clinical Trial Key Non-Alcoholic Steatohepatitis (NASH) Companies include Novo Nordisk, Viking Therapeutics, Inventiva Pharma, GlaxoSmithKline, Haisco Pharmaceutical Group, and others The Non-Alcoholic Steatohepatitis (NASH) therapeutic landscape is entering a pivotal phase of innovation and clinical acceleration, driven by … Continue reading →

STAT Inhibitors Pipeline Set for Breakthrough Innovation by 2026 with 22+ Therapies and Expanding Clinical Momentum | DelveInsight

STAT Inhibitors Clinical Trials Key STAT Inhibitors Companies include Tvardi Therapeutics, Kymera Therapeutics, Recludix Pharma, Enanta Pharmaceuticals, Moleculin, Purple Biotech, LEO Pharma, JW Pharmaceutical, KAKEN PHARMACEUTICAL, C4XD Holdings, and others The STAT inhibitors therapeutic landscape is undergoing a significant transformation, … Continue reading →

Diabetic Neuropathy Pipeline Set for Significant Breakthroughs by 2026 with 20+ Therapies and Robust Clinical Advancements | DelveInsight

Diabetic Neuropathy Clinical Trial Leading diabetic neuropathy companies include Vertex Pharmaceuticals Incorporated, Novaremed, Trevena, Inc., WinSanTor, Inc., AlgoTherapeutix, Tris Pharma, Inc., JMackem Co., Ltd, Lexicon Pharmaceuticals, Merz Pharmaceuticals GmbH, and others are evaluating new diabetic neuropathy drugs to improve the … Continue reading →

Acute on Chronic Liver Failure Pipeline Set for Strategic Expansion by 2026 with Emerging Gene Therapies and Novel Mechanisms from Genfit and Gyre Therapeutics | DelveInsight

Acute on Chronic Liver Failure Clinical Trial The Acute on Chronic Liver Failure therapeutic pipeline is witnessing a gradual but significant evolution, driven by increasing understanding of disease mechanisms and unmet clinical needs. The pipeline is currently composed of 5+ … Continue reading →

Sandwich Panels Market Valued at USD 16.52 Billion in 2026 to Witness 5.12% CAGR Through 2031 Fueled by Industrial and Cold Chain Expansion

Sandwich Panels Market Explore the Sandwich Panels market (2026–2031) with Mordor Intelligence. Get in-depth insights on market size, share, revenue, segments, key drivers, latest trends, and growth opportunities shaping the future of sustainable construction. The Sandwich panels Market continues to … Continue reading →

DigiMarCon Singapore 2026 Returns to Singapore, Bringing the Future of Digital Marketing to the Global Stage

Singapore – DigiMarCon Singapore, the premier digital marketing, media, advertising, and business conference and exhibition in the Singapore, will return August 26-27, 2026, at the Four Points by Sheraton Singapore Riverview Hotel in Singapore. The three-day event will unite marketers, … Continue reading →